Full adoption of biosimilars will require proper provider and patient education, payer coverage navigation support, and streamlined workflows.
An analysis of the immunotherapy combination compared with sunitinib placed the combo on the high end of willingness-to-pay thresholds for cancer drugs.
Integrating mutation-specific data across repositories and portals may lead to novel therapeutically actionable insights for acute myeloid leukemia.
Researchers establish a Chinese-specific BRCA database to cover nearly all of the BRCA variation information currently known across this population.
CAR-T’s inability to induce durable remissions in many patients is a barrier to the success of these adoptive cell therapies—but solutions are under way.